I thought I would share this article from McKinsey on the potential shape of things to come. Clearly the Covid-19 pandemic has changed our world in the short-term, the real question however is how has this potentially shaped our world in the long-term? One part that particularly caught my eye ‘Greater automation was already occurring…
Domestic drug manufacturing requirements I have commented previously on the need to bring manufacturing back home to the US. As the COVID-19 pandemic lingers on, and supply chains become more strained the need to bring manufacturing of all types, but specifically for pharmaceuticals becomes painfully more apparent. There are many high-quality FDA approved facilities in…
D2 has had the privilege of working with over 350 pharmaceutical, biotech and medical device manufacturers. Much of what we have supported on behalf of these organizations is the selection of “vendors” for a variety of services across the supply chain including their 3PL, Distribution, Specialty Pharmacy, HUB, Support Vendors (copay, pap, data aggregators etc.)….
One of the big industry challenges is getting specialty medications to patients. Manufacturer’s tell us the drop off between when a prescription is written to patient receipt is as high as 50%. What causes this drop-off, simplistically “the system”. The system is many disparate pieces within an onboarding and product delivery model that doesn’t work…
The value-based Triple Aim movement. Undeniable, or undeniably difficult? Enjoy this article from D2’s Kirby Eng outlining the difficulties, but also opportunities based on digital solutions that can encompass real-world, patient reported outcomes. Getting patients more engaged in their healthcare, the true healthcare revolution.